Salmasi S, et al. - In patients with systemic lupus erythematosus (SLE; a chronic systemic autoimmune disease affecting most body systems), researchers used administrative health databases in British Columbia, Canada to explore the connection between adherence to antimalarials (eg, hydroxychloroquine and chloroquine) and T2DM. Participants in the study were 1,498 SLE patients (mean age was 44.4 ± 14.8 years). According to this retrospective, longitudinal cohort study, compared with those who stopped their therapy, adherent patients were 39% less prone to develop T2DM. The protective effect against T2DM is lost when taking less than 90% of the prescribed doses of antimalarials. Overall, the research provides additional support for the value of adherence to antimalarials in SLE by showing protective impacts on T2DM, a serious complication of SLE.